Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05821777 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate Safety, Tolerability and Preliminary Activity of LB101 in Participants With Advanced Solid Tumors
A Phase 1 study, sponsored by Centessa Pharmaceuticals (UK) Limited.
- Terminated
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT05821777 is a Phase 1 study that was terminated before completion, run by Centessa Pharmaceuticals (UK) Limited. The registered enrollment target is 25 participants.
The verdict
NCT05821777, a Phase 1 study, was terminated before completion, sponsored by Centessa Pharmaceuticals (UK) Limited.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
The purpose of this study is to assess safety, tolerability, and preliminary activity of LB101 monotherapy in participants with advanced solid tumors.
Interventions
- DRUG LB101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2023-03-28 |
| Est. Completion | 2025-09-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05821777
The ClinicalTrials.gov registry entry for NCT05821777 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Centessa Pharmaceuticals (UK) Limited, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which LB101 is the first listed.
NCT05821777 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05821777 about?
NCT05821777 is a clinical study titled "A Study to Evaluate Safety, Tolerability and Preliminary Activity of LB101 in Participants With Advanced Solid Tumors". The purpose of this study is to assess safety, tolerability, and preliminary activity of LB101 monotherapy in participants with advanced solid tumors.
What is the current status of trial NCT05821777?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2023-03-28. Estimated completion is 2025-09-09.
What interventions are being tested in trial NCT05821777?
The interventions under investigation include: LB101 (DRUG).
Who is sponsoring clinical trial NCT05821777?
This trial is sponsored by Centessa Pharmaceuticals (UK) Limited, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.